Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The image shows stained cells in two rose: a comparision between the top row (displaying normal cells) versus the bottom row (showing ATRX deficient bottom row) shows that there are many more trapped TOP1 proteins in the bottom row image.

Work led by Dr Anna Rose and DPhil student Tomas Goncalves has unpicked a key DNA interaction that leads cells to become cancerous via a particular pathway that causes up to 80% of the cancers affecting children and young people.

ALT cancers, as they are known, all have a commonality: the cancer cells in this group of cancers all have elongated telomeres achieved via process called Alternative Lengthening of Telomeres (ALT). Such elongated telomeres are a key feature of cancer cells – elongating their telomeres (the protective end cap on chromosomes) allow cancer cells to divide endlessly, escaping the normal programme of cell death that regulates other cells when they are no longer useful to the body.

Researchers also know that the loss of the ATRX gene is a central genetic event which leads to the development of ALT cancers, but previous work has also shown that this alone is not enough to transform a normal cell into a cancerous one- a second factor is required. The central genetic event in the development of ALT cancers is the loss of the ATRX gene. However, it has been shown that loss of ATRX is not sufficient to transform a normal cell into a cancerous cell -- a second factor is required. 

Now a study published in Nucleic Acids Research has found that excessive ‘trapping’ of DNA-interacting proteins onto the DNA is likely to be the second causative factor driving development of the ALT pathway. In the study, the research team (which included researchers from the Department of Oncology, with Dr David Clynes as senior study author), researchers treated cells with several drugs ('trapping agents), which cause damage by sticking proteins tightly to the DNA strand, causing a physical blockade. These drugs are used clinically as chemotherapy – because DNA damaging agents are highly effective at killing fast dividing cells, such as cancer cells. However, DNA damage is also the initial cause of cancer and so the same drugs can be used to study the origins of the disease.

Dr Rose said “We found that treating cells without the ATRX gene with these trapping agents set off the ALT pathway, but did not affect ATRX-expressing cells.” (the main image's top row shows normal cells, while the bottom row shows ATRX deficient ALT cancer cells. The green dots in the middle panel shows trapped TOP1 protens - the bottom row shows a massive increase in these in ALT cells).

Dr Rose added “We also found that compared to non-ALT cancer cells, ALT cancer cells from patients had higher levels of trapped proteins. Our ongoing work is exploring why these cells have accumulated trapped proteins – we hope that these insights into the underpinning molecular mechanisms will give rise to new therapeutic approaches."

Read the study.

Recent stories

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead and Beth Psaila, has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs).

New technology helps decode the genetic changes behind disease

Researchers from the Milne, Hughes and Davies Groups have developed a new technology that can reveal new therapeutic targets from common genetic variants linked to disease.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Professor Marella de Bruijn receives MRC Programme Award

Congratulations to Professor de Bruijn, who has been awarded funding from the UKRI Medical Research Council to investigate how the first blood stem cells formed in the embryo acquire their exceptional regenerative potential, with the aim of informing future stem cell therapies.

Professor Bethan Psaila wins ISEH Janet Rowley Award

Congratulations to Professor Psaila, who has received the 2026 Janet Rowley Award from the International Society for Experimental Hematology, in recognition of her outstanding contributions in the field of experimental haematology.

Professor KJ Patel awarded Royal Society Buchanan Medal

Congratulations to Professor Patel, who has received the Buchanan Medal, which recognises distinguished contributions to the biomedical sciences.